Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.46 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 7/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4920729 | 0.90 | HSD17B10 (0.47) | MAP3K12MAPK1HSD17B10L3MBTL1KDM4E | |
| SCHEMBL14184758 | 0.84 | SCN9A (0.42) | MAPK1HSD17B10RPS6KB1 | |
| SCHEMBL4923945 | 0.84 | SYK (0.44) | MAP3K12MAPK1HSD17B10L3MBTL1RPS6KB1 | |
| SCHEMBL4928603 | 0.81 | HSD17B10 (0.41) | MAP3K12MAPK1HSD17B10L3MBTL1KDM4E | |
| SCHEMBL4923497 | 0.79 | RPS6KB1 (0.42) | RPS6KB1 | |
| SCHEMBL4929454 | 0.79 | MTOR (0.46) | PIK3CAMTOR | |
| SCHEMBL14184766 | 0.79 | MTOR (0.46) | PIK3CAMTOR | |
| SCHEMBL4931016 | 0.75 | SCN9A (0.35) | MAPK1HSD17B10RPS6KB1 | |
| SCHEMBL4923903 | 0.74 | RPS6KB1 (0.39) | MAP3K12RPS6KB1 | |
| SCHEMBL4927406 | 0.71 | MKNK1 (0.41) | RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | PIK3CA 756/4885MAP3K12 2454/4885MTOR 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.